Article info

Original research
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Authors

  1. Correspondence to Dr Sandra P D'Angelo; dangelos{at}mskcc.org
View Full Text

Citation

D'Angelo SP, Lebbé C, Mortier L, et al
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

Publication history

  • Accepted May 2, 2021
  • First published July 23, 2021.
Online issue publication 
July 23, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.